Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825698 | 0.91 | LMNA (0.49) | LMNAMAPTKDM4EPOLBTP53 | |
| SCHEMBL16825906 | 0.87 | P2RX7 (0.48) | LMNAKDM4EPOLBTP53KMT2A | |
| SCHEMBL18135562 | 0.86 | LMNA (0.63) | LMNAMAPTKDM4EPOLBTP53 | |
| SCHEMBL16825925 | 0.86 | LMNA (0.59) | LMNAMAPTKDM4EPOLBTSHR | |
| SCHEMBL16826303 | 0.85 | MAPT (0.49) | LMNAMAPTPOLBTP53KMT2A | |
| SCHEMBL16825843 | 0.84 | ALDH1A1 (0.50) | LMNAMAPTPOLBKMT2ATDP1 | |
| SCHEMBL16825669 | 0.83 | CA12 (0.52) | LMNAMAPTKDM4EPOLBTP53 | |
| SCHEMBL16825712 | 0.82 | LMNA (0.50) | LMNAKDM4EPOLBTP53TDP1 | |
| SCHEMBL16826124 | 0.82 | TDP1 (0.67) | LMNAMAPTPOLBTP53TSHR | |
| SCHEMBL16825726 | 0.81 | LMNA (0.52) | LMNAMAPTKDM4EPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | LMNA 3856/4885MAPT 2060/4885KDM4E 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.